Asparaginase-associated toxicity in children with acute lymphoblastic leukemia

References

• Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet 2008; 371: 1030–1043.
   PubMed Web of Science ®Google Scholar
• Hunger SP, Loh ML, Whitlock JA, et al. Children’s Oncology Group’s 2013 blueprint for research: acute lymphoblastic leukemia. Pediatr Blood Cancer 2013; 60: 957–963.
   PubMed Web of Science ®Google Scholar
• Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 2001; 97: 1211–1218.
   PubMed Web of Science ®Google Scholar
• Pession A, Valsecchi MG, Masera G, et al. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia. J Clin Oncol 2005; 23: 7161–7167.
   PubMed Web of Science ®Google Scholar
• Amylon MD, Shuster J, Pullen J, et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia 1999; 13: 335–342.
   PubMed Web of Science ®Google Scholar
• Stock W. Adolescents and young adults with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2010; 2010: 21–29.
   PubMed Web of Science ®Google Scholar
• Raetz EA, Salzer WL. Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2010; 32: 554–563.
   PubMed Web of Science ®Google Scholar
• Muller HJ, Boos J. Use of L-asparaginase in childhood ALL. Crit Rev Oncol Hematol 1998; 28: 97–113.
   PubMed Web of Science ®Google Scholar
• Riccardi R, Holcenberg JS, Glaubiger DL, Wood JH, Poplack DG. L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. Cancer Res 1981; 41: 4554–4558.
   PubMed Web of Science ®Google Scholar
• Panetta JC, Gajjar A, Hijiya N, et al. Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia. Clin Pharmacol Ther 2009; 86: 651–658.
   PubMed Web of Science ®Google Scholar
• Keding R. RE: Discontinuation of Elspar®, (asparaginase for injection) 10,000 IU; August 12, 2012. Accessed July 30, 2014 from: http://www.fda.gov/downloads/Drugs/DrugSafety/DrugShortages/UCM321556.pdf.
   Google Scholar
• Salzer W, Seibel N, Smith M. Erwinia asparaginase in pediatric acute lymphoblastic leukemia. Expert Opin Biol Ther 2012; 12: 1407–1414.
   PubMed Web of Science ®Google Scholar
• Zalewska-Szewczyk B, Gach A, Wyka K, Bodalski J, Mlynarski W. The cross-reactivity of anti-asparaginase antibodies against different L-asparaginase preparations. Clin Exp Med 2009; 9: 113–116.
   PubMed Web of Science ®Google Scholar
• ERWINAZE [package insert]. Palo Alto, CA: Jazz Pharmaceuticals, Inc.; 2014. Accessed January 30, 2015 from: http://erwinaze.com/ERWINAZEPI.pdf
   Google Scholar
• Asselin BL, Whitin JC, Coppola DJ, Rupp IP, Sallan SE, Cohen HJ. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 1993; 11: 1780–1786.
   PubMed Web of Science ®Google Scholar
• Avramis VI, Panosyan EH. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Clin Pharmacokinet 2005; 44: 367–393.
   PubMed Web of Science ®Google Scholar
• Douer D, Yampolsky H, Cohen LJ, et al. Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood 2007; 109: 2744–2750.
   PubMed Web of Science ®Google Scholar
• Angiolillo AL, Schore RJ, Devidas M, et al. Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4. J Clin Oncol 2014; 32: 3874–3882.
   PubMed Web of Science ®Google Scholar
• Asselin BL. The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia. Adv Exp Med Biol 1999; 457: 621–629.
   PubMed Web of Science ®Google Scholar
• Pieters R, Hunger SP, Boos J, et al. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer 2011; 117: 238–249.
   PubMed Web of Science ®Google Scholar
• Wacker P, Land VJ, Camitta BM, et al. Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: a Children’s Oncology Group Study. J Pediatr Hematol Oncol 2007; 29: 627–632.
   PubMed Web of Science ®Google Scholar
• Muller HJ, Beier R, Loning L, et al. Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment. Br J Haematol 2001; 114: 794–799.
   PubMed Web of Science ®Google Scholar
• Woo MH, Hak LJ, Storm MC, et al. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol 2000; 18: 1525–1532.
   PubMed Web of Science ®Google Scholar
• Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children’s Cancer Group study. Blood 2002; 99: 1986–1994.
   PubMed Web of Science ®Google Scholar
• Panosyan EH, Seibel NL, Martin-Aragon S, et al. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children’s Cancer Group Study CCG-1961. J Pediatr Hematol Oncol 2004; 26: 217–226.
   PubMed Web of Science ®Google Scholar
• Vrooman LM, Supko JG, Neuberg DS, et al. Erwinia asparaginase after allergy to E coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2010; 54: 199–205.
   PubMed Web of Science ®Google Scholar
• Seibel NL, Steinherz PG, Sather HN, et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Blood 2008; 111: 2548–2555.
   PubMed Web of Science ®Google Scholar
• Billett AL, Carls A, Gelber RD, Sallan SE. Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase. Cancer 1992; 70: 201–206.
   PubMed Web of Science ®Google Scholar
• Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 2007; 109: 896–904.
   PubMed Web of Science ®Google Scholar
• Albertsen BK, Schroder H, Jakobsen P, et al. Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase. Med Pediatr Oncol 2002; 38: 310–316.
   PubMedGoogle Scholar
• Albertsen BK, Schroder H, Jakobsen P, et al. Monitoring of Erwinia asparaginase therapy in childhood ALL in the Nordic countries. Br J Clin Pharmacol 2001; 52: 433–437.
   PubMed Web of Science ®Google Scholar
• Tong WH, Pieters R, Kaspers GJ, et al. A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. Blood 2014; 123: 2026–2033.
   PubMed Web of Science ®Google Scholar
• Salzer WL, Asselin B, Supko JG, et al. Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children’s Oncology Group. Blood 2013; 122: 507–514.
   PubMed Web of Science ®Google Scholar
• Plourde PV, Jeha S, Hijiya N, et al. Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial. Pediatr Blood Cancer 2014; 61: 1232–1238.
   PubMed Web of Science ®Google Scholar
• Hak LJ, Relling MV, Cheng C, et al. Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia. Leukemia 2004; 18: 1072–1077.
   PubMed Web of Science ®Google Scholar
• Liu C, Kawedia JD, Cheng C, et al. Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia. Leukemia 2012; 26: 2303–2309.
   PubMed Web of Science ®Google Scholar
• Vrooman LM, Stevenson KE, Supko JG, et al. Postinduction dexamethasone and individualized dosing of Escherichia coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study – Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. J Clin Oncol 2013; 31: 1202–1210.
   PubMed Web of Science ®Google Scholar
• Howard SC, Pui CH. Endocrine complications in pediatric patients with acute lymphoblastic leukemia. Blood Rev 2002; 16: 225–243.
   PubMed Web of Science ®Google Scholar
• Raja RA, Schmiegelow K, Albertsen BK, et al. Asparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia in the NOPHO ALL2008 protocol. Br J Haematol 2014; 165: 126–133.
   PubMed Web of Science ®Google Scholar
• Stock W, Douer D, DeAngelo DJ, et al. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma 2011; 52: 2237–2253.
   PubMed Web of Science ®Google Scholar
• Payne JH, Vora AJ. Thrombosis and acute lymphoblastic leukaemia. Br J Haematol 2007; 138: 430–445.
   PubMed Web of Science ®Google Scholar
• Truelove E, Fielding AK, Hunt BJ. The coagulopathy and thrombotic risk associated with L-asparaginase treatment in adults with acute lymphoblastic leukaemia. Leukemia 2013; 27: 553–559.
   PubMed Web of Science ®Google Scholar
• Grace RF, Dahlberg SE, Neuberg D, et al. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol 2011; 152: 452–459.
   PubMed Web of Science ®Google Scholar
• Panis B, Vlaar AM, van Well GT, et al. Posterior reversible encephalopathy syndrome in paediatric leukaemia. Eur J Paediatr Neurol 2010; 14: 539–545.
   PubMed Web of Science ®Google Scholar
• Merryman R, Stevenson KE, Gostic WJ, 2nd, et al. Asparaginase-associated myelosuppression and effects on dosing of other chemotherapeutic agents in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2012; 59: 925–927.
   PubMed Web of Science ®Google Scholar
• Tong WH, Pieters R, de Groot-Kruseman HA, et al. Toxicity of very prolonged PEGasparaginase and Erwinia asparaginase courses in relation to asparaginase activity levels with a special focus on dyslipidemia. Haematologica 2014; 99: 1716–1721.
   PubMed Web of Science ®Google Scholar
• Bhojwani D, Darbandi R, Pei D, et al. Severe hypertriglyceridaemia during therapy for childhood acute lymphoblastic leukaemia. Eur J Cancer 2014; 50: 2685–2694.
   PubMed Web of Science ®Google Scholar
• Panosyan EH, Grigoryan RS, Avramis IA, et al. Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961). Anticancer Res 2004; 4(2C): 1121–1125.
   Google Scholar
• Zalewska-Szewczyk B, Andrzejewski W, Mlynarski W, et al. The anti-asparagines antibodies correlate with L-asparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia. Leuk Lymphoma 2007; 48: 931–936.
   PubMed Web of Science ®Google Scholar
• Kawahara Y, Morimoto A, Hayase T, et al. Monitoring of anti-L-asparaginase antibody and L-asparaginase activity levels in a pediatric patient with acute lymphoblastic leukemia and hypersensitivity to native Escherichia coli L-asparaginase during desensitization courses. J Pediatr Hematol Oncol 2014; 36: e91–e93.
   PubMed Web of Science ®Google Scholar
• Burke MJ. How to manage asparaginase hypersensitivity in acute lymphoblastic leukemia. Future Oncol 2014; 10: 2615–2627.
   PubMed Web of Science ®Google Scholar
• Wang B, Relling MV, Storm MC, et al. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients. Leukemia 2003; 17: 1583–1588.
   PubMed Web of Science ®Google Scholar
• Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007; 12: 601–609.
   PubMed Web of Science ®Google Scholar
• Carpentieri U, Balch MT. Hyperglycemia associated with the therapeutic use of L-asparaginase: possible role of insulin receptors. J Pediatr 1978; 93: 775–778.
   PubMed Web of Science ®Google Scholar
• Olefsky JM, Kimmerling G. Effects of glucocorticoids on carbohydrate metabolism. Am J Med Sci 1976; 271: 202–210.
   PubMed Web of Science ®Google Scholar
• Chan JC, Cockram CS, Critchley JA. Drug-induced disorders of glucose metabolism. Mechanisms and management. Drug Saf 1996; 15: 135–157.
   PubMed Web of Science ®Google Scholar
• Pui CH, Burghen GA, Bowman WP, et al. Risk factors for hyperglycemia in children with leukemia receiving L-asparaginase and prednisone. J Pediatr 1981; 99: 46–50.
   PubMed Web of Science ®Google Scholar
• Lowas SR, Marks D, Malempati S. Prevalence of transient hyperglycemia during induction chemotherapy for pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer 2009; 52: 814–818.
   PubMed Web of Science ®Google Scholar
• Cetin M, Yetgin S, Kara A, et al. Hyperglycemia, ketoacidosis and other complications of L-asparaginase in children with acute lymphoblastic leukemia. J Med 1994; 25: 219–229.
   PubMedGoogle Scholar
• Belgaumi AF, Al-Bakrah M, Al-Mahr M, et al. Dexamethasone-associated toxicity during induction chemotherapy for childhood acute lymphoblastic leukemia is augmented by concurrent use of daunomycin. Cancer 2003; 97: 2898–2903.
   PubMed Web of Science ®Google Scholar
• Raja RA, Schmiegelow K, Frandsen TL. Asparaginase-associated pancreatitis in children. Br J Haematol 2012; 159: 18–27.
   PubMed Web of Science ®Google Scholar
• Kearney SL, Dahlberg SE, Levy DE, et al. Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis. Pediatr Blood Cancer 2009; 53: 162–167.
   PubMed Web of Science ®Google Scholar
• Knoderer HM, Robarge J, Flockhart DA. Predicting asparaginase-associated pancreatitis. Pediatr Blood Cancer 2007; 49: 634–639.
   PubMed Web of Science ®Google Scholar
• Samarasinghe S, Dhir S, Slack J, et al. Incidence and outcome of pancreatitis in children and young adults with acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. Br J Haematol 2013; 162: 710–713.
   PubMed Web of Science ®Google Scholar
• Treepongkaruna S, Thongpak N, Pakakasama S, et al. Acute pancreatitis in children with acute lymphoblastic leukemia after chemotherapy. J Pediatr Hematol Oncol 2009; 31: 812–815.
   PubMed Web of Science ®Google Scholar
• Hernandez-Espinosa D, Minano A, Martinez C, et al. L-asparaginase-induced antithrombin type I deficiency: implications for conformational diseases. Am J Pathol 2006; 169: 142–153.
   PubMed Web of Science ®Google Scholar
• Mitchell LG, Halton JM, Vegh PA, et al. Effect of disease and chemotherapy on hemostasis in children with acute lymphoid leukemia. Am J Pediatr Hematol Oncol 1994; 16: 120–126.
   PubMedGoogle Scholar
• Hongo T, Okada S, Ohzeki T, et al. Low plasma levels of hemostatic proteins during the induction phase in children with acute lymphoblastic leukemia: a retrospective study by the JACLS. Japan Association of Childhood Leukemia Study. Pediatr Int 2002; 44: 293–299.
   PubMed Web of Science ®Google Scholar
• Mitchell L, Hoogendoorn H, Giles AR, et al. Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in l’asparaginase-induced antithrombin III deficiency. Blood 1994; 83: 386–391.
   PubMed Web of Science ®Google Scholar
• Andrew M, Brooker L, Mitchell L. Acquired antithrombin III deficiency secondary to asparaginase therapy in childhood acute lymphoblastic leukaemia. Blood Coagul Fibrinolysis 1994; 5(Suppl. 1): S24–S36; discussion S59–S64.
   PubMed Web of Science ®Google Scholar
• Caruso V, Iacoviello L, Di Castelnuovo A, et al. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood 2006; 108: 2216–2222.
   PubMed Web of Science ®Google Scholar
• Nowak-Gottl U, Kenet G, Mitchell LG. Thrombosis in childhood acute lymphoblastic leukaemia: epidemiology, aetiology, diagnosis, prevention and treatment. Best Pract Res Clin Haematol 2009; 22: 103–114.
   PubMed Web of Science ®Google Scholar
• Qureshi A, Mitchell C, Richards S, et al. Asparaginase-related venous thrombosis in UKALL 2003 – re-exposure to asparaginase is feasible and safe. Br J Haematol 2010; 149: 410–413.
   PubMed Web of Science ®Google Scholar
• Nowak-Gottl U, Wermes C, Junker R, et al. Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. Blood 1999; 93: 1595–1599.
   PubMed Web of Science ®Google Scholar
• Mauz-Korholz C, Junker R, Gobel U, et al. Prothrombotic risk factors in children with acute lymphoblastic leukemia treated with delayed E. coli asparaginase (COALL-92 and 97 protocols). Thromb Haemost 2000; 83: 840–843.
   PubMed Web of Science ®Google Scholar
• Mitchell LG, Andrew M, Hanna K, et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study. Cancer 2003; 97: 508–516.
   PubMed Web of Science ®Google Scholar
• Wermes C, von Depka Prondzinski M, et al. Clinical relevance of genetic risk factors for thrombosis in paediatric oncology patients with central venous catheters. Eur J Pediatr 1999; 158: S143–S146.
   PubMed Web of Science ®Google Scholar
• Elhasid R, Lanir N, Sharon R, et al. Prophylactic therapy with enoxaparin during L asparaginase treatment in children with acute lymphoblastic leukemia. Blood Coagul Fibrin 2001; 12: 367–370.
   PubMed Web of Science ®Google Scholar
• Jaing TH, Lin JL, Lin YP, et al. Hyperammonemic encephalopathy after induction chemotherapy for acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2009; 31: 955–956.
   PubMed Web of Science ®Google Scholar
• Frantzeskaki F, Rizos M, Papathanassiou M, et al. L-asparaginase fatal toxic encephalopathy during consolidation treatment in an adult with acute lymphoblastic leukemia. Am J Case Rep 2013; 14: 311–314.
   PubMedGoogle Scholar
• Morris EB, Laningham FH, Sandlund JT, et al. Posterior reversible encephalopathy syndrome in children with cancer. Pediatr Blood Cancer 2007; 48: 152–159.
   PubMed Web of Science ®Google Scholar
• Norman JK, Parke JT, Wilson DA, et al. Reversible posterior leukoencephalopathy syndrome in children undergoing induction therapy for acute lymphoblastic leukemia. Pediatr Blood Cancer 2007; 49: 198–203.
   PubMed Web of Science ®Google Scholar
• D’Angelo P, Farruggia P, Lo Bello A, et al. Reversible posterior leukoencephalopathy syndrome: report of 2 simultaneous cases in children. J Pediatr Hematol Oncol 2006; 28: 177–181.
   PubMed Web of Science ®Google Scholar
• Sudour H, Schmitt C, Contet A, et al. Acute metabolic encephalopathy in two patients treated with asparaginase and ondasetron. Am J Hematol 2011; 86: 323–325.
   PubMed Web of Science ®Google Scholar
• Butterworth RF. Pathophysiology of brain dysfunction in hyperammonemic syndromes: the many faces of glutamine. Mol Genet Metab 2014; 113: 113–117.
   PubMed Web of Science ®Google Scholar
• Jorck C, Kiess W, Weigel JF, et al. Transient hyperammonemia due to L-asparaginase therapy in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma. Pediatr Hematol Oncol 2011; 28: 3–9.
   PubMed Web of Science ®Google Scholar
• D’Onofrio V, Poma F, Enea A, et al. Hyperammonemic coma in a patient with late-onset OTC deficiency. Pediatr Med Chir 2014; 36: 9.
   PubMedGoogle Scholar
• Johnston PG, Hardisty RM, Kay HE, et al. Myelosuppressive effect of colaspase (L-asparaginase) in initial treatment of acute lymphoblastic leukaemia. Br Med J 1974; 3: 81–83.
   PubMed Web of Science ®Google Scholar
• Oehlers MJ, Fetawadjieff W, Woodliff HJ. Profound leukopenia following asparaginase treatment in a patient with acute lymphoblastic leukaemia. Med J Aust 1969; 2: 907–909.
   PubMedGoogle Scholar
• Harris MB, Shuster JJ, Pullen J, et al. Treatment of children with early pre-B and pre-B acute lymphocytic leukemia with antimetabolite-based intensification regimens: a Pediatric Oncology Group Study. Leukemia 2000; 14: 1570–1576.
   PubMed Web of Science ®Google Scholar
• Salzer WL, Devidas M, Shuster JJ, et al. Intensified PEG-L-asparaginase and antimetabolite-based therapy for treatment of higher risk precursor-B acute lymphoblastic leukemia: a report from the Children’s Oncology Group. J Pediatr Hematol Oncol 2007; 29: 369–375.
   PubMed Web of Science ®Google Scholar
• Cremer P, Lakomek M, Beck W, et al. The effect of L-asparaginase on lipid metabolism during induction chemotherapy of childhood lymphoblastic leukaemia. Eur J Pediatr 1988; 147: 64–67.
   PubMed Web of Science ®Google Scholar
• Steinherz PG. Transient, severe hyperlipidemia in patients with acute lymphoblastic leukemia treated with prednisone and asparaginase. Cancer 1994; 74: 3234–3239.
   PubMed Web of Science ®Google Scholar
• Solano-Paez P, Villegas JA, Colomer I, et al. L-asparaginase and steroids-associated hypertriglyceridemia successfully treated with plasmapheresis in a child with acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2011; 33: e122–e124.
   PubMed Web of Science ®Google Scholar
• Parsons SK, Skapek SX, Neufeld EJ, et al. Asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia. Blood 1997; 89: 1886–1895.
   PubMed Web of Science ®Google Scholar
• Salvador C, Meister B, Crazzolara R, et al. Management of hypertriglyceridemia in children with acute lymphoblastic leukemia under persistent therapy with glucocorticoids and L-asparaginase during induction chemotherapy. Pediatr Blood Cancer 2012; 59: 771.
   PubMed Web of Science ®Google Scholar
• Ridola V, Buonuomo PS, Maurizi P, et al. Severe acute hypertriglyceridemia during acute lymphoblastic leukemia induction successfully treated with plasmapheresis. Pediatr Blood Cancer 2008; 50: 378–380.
   PubMed Web of Science ®Google Scholar
• Cohen H, Bielorai B, Harats D, et al. Conservative treatment of L-asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2010; 54: 703–706.
   PubMed Web of Science ®Google Scholar
• Berrueco R, Rives S, Lopez-Garcia VS, et al. Very high hypertriglyceridemia induced: is plasmapheresis needed? Pediatr Blood Cancer 2011; 57: 532.
   PubMed Web of Science ®Google Scholar
• Abourbih S, Filion KB, Joseph L, et al. Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review. Am J Med 2009; 122: 962. e1–e8.
   PubMed Web of Science ®Google Scholar
• Bostrom B. Successful management of extreme hypertriglyceridemia from pegaspargase with omega-3. Pediatr Blood Cancer 2012; 59: 350.
   PubMed Web of Science ®Google Scholar
• Tong WH, Pieters R, van der Sluis IM. Successful management of extreme hypertriglyceridemia in a child with acute lymphoblastic leukemia by temporarily omitting dexamethasone while continuing asparaginase. Pediatr Blood Cancer 2012; 58: 317–318.
   PubMed Web of Science ®Google Scholar
• Dinndorf PA, Gootenberg J, Cohen MH, et al. FDA drug approval summary: pegaspargase (Oncaspar®) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist 2007; 12: 991–998.
   PubMed Web of Science ®Google Scholar
• Kurre HA, Ettinger AG, Veenstra DL, et al. A pharmacoeconomic analysis of pegaspargase versus native Escherichia coli L-asparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: the Children’s Cancer Group study (CCG-1962). J Pediatr Hematol Oncol 2002; 24: 175–181.
   PubMed Web of Science ®Google Scholar
• Duval M, Suciu S, Ferster A, et al. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children’s Leukemia Group phase 3 trial. Blood 2002; 99: 2734–2739.
   PubMed Web of Science ®Google Scholar
• Dutch Childhood Oncology Group. Treatment study protocol of the Dutch Childhood Oncology Group for children and adolescents (1–19 year) with newly diagnosed acute lymphoblastic leukemia; April 10, 2013. Accessed December 1, 2014 from: https://www.skion.nl/workspace/uploads/Onderzoeksprotocol-ALL11-version-4-1-april-2013.pdf
   Google Scholar
• Douer D. Is asparaginase a critical component in the treatment of acute lymphoblastic leukemia? Best Pract Res Clin Haematol 2008; 21: 647–658.
   PubMed Web of Science ®Google Scholar
• Boissel N, Auclerc MF, Lhéritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 2003; 21: 774–780.
   PubMed Web of Science ®Google Scholar
• Stock W, La M, Sanford B, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children’s Cancer Group and Cancer and Leukemia Group B studies. Blood 2008; 112: 1646–1654.
   PubMed Web of Science ®Google Scholar
• de Bont JM, Holt B, Dekker AW, et al. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia 2004; 18: 2032–2035.
   PubMed Web of Science ®Google Scholar
• Hallbook H, Gustafsson G, Smedmyr B, et al. Treatment outcome in young adults and children >10 years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol. Cancer 2006; 107: 1551–1561.
   PubMed Web of Science ®Google Scholar
• Ramanujachar R, Richards S, Hann I, et al. Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials. Pediatr Blood Cancer 2007; 48: 254–261.
   PubMed Web of Science ®Google Scholar
• Advani AS, Sanford B, Luger S, et al. Frontline-treatment of acute lymphoblastic leukemia (ALL) in older adolescents and young adults (AYA) using a pediatric regimen is feasible: toxicity results of the prospective US intergroup trial C10403 (Alliance) [abstract]. Blood 2013; 122: Abstract 3903.
   Web of Science ®Google Scholar